Compounds > n-succinimidyl-3-(tri-n-butylstannyl)benzoate
Page last updated: 2024-12-07

n-succinimidyl-3-(tri-n-butylstannyl)benzoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID130716
SCHEMBL ID317623
MeSH IDM0155412

Synonyms (13)

Synonym
stbsb
(2,5-dioxopyrrolidin-1-yl) 3-tributylstannylbenzoate
n-succinimidyl-3-(tri-n-butylstannyl)benzoate
m-buate
2,5-pyrrolidinedione, 1-((3-(tributylstannyl)benzoyl)oxy)-
112725-22-1
SCHEMBL317623
n-succinimidyl 3-(tri-n-butylstannyl)benzoate
succinimidyl 3-(tri-n-butylstannyl)benzoate
DTXSID90150149
2,5-pyrrolidinedione, 1-[[3-(tributylstannyl)benzoyl]oxy]-
mfcd01863152
2,5-dioxopyrrolidin-1-yl 3-(tributylstannyl)benzoate

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In addition, 81C6 ATE administered at this dosage to animals with 50% larger initial tumors also improved tumor growth delay in comparison with 81C6 IOD given to animals with standard-size tumors."( Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
Bigner, DD; Garg, PK; Schuster, JM; Zalutsky, MR, 1991)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (50.00)18.7374
1990's3 (37.50)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.07 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.110isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril
1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenylglycoluril: reagent for protein iodinations; structure		2.110
n-succinimidyl 3-iodobenzoate
[no description available]		2.110
n-succinimidyl 3-(trimethylstannyl)benzoate
N-succinimidyl 3-(trimethylstannyl)benzoate: structure given in first source		1.9710
astatine
Astatine: Astatine. A radioactive halogen with the atomic symbol At, and atomic number 85. Its isotopes range in mass number from 200 to 219 and all have an extremely short half-life. Astatine may be of use in the treatment of hyperthyroidism because it emits ALPHA PARTICLES.		3.4720elemental astatine
ConditionIndicatedRelationship StrengthStudiesTrials
Glial Cell Tumors
[description not available]		02.3820
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.3820
Experimental Neoplasms
[description not available]		01.9710
Benign Neoplasms, Brain
[description not available]		01.9710
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		01.9710